About
TianTi Biotherapeutics utilizes its AbLink™, OptAb™, and Rapid VHH technology platforms to efficiently mine the natural immune repertoire for high-affinity antibodies, enhancing hit success rates in therapeutic discovery. The company addresses the challenge of limited therapeutic options by generating diverse and functional antibody candidates without the need for mammalian cell validation.
```xml <problem> Discovering high-affinity antibodies for therapeutic development is challenging due to the limited diversity and functionality of antibody candidates generated through traditional methods. Many approaches require mammalian cell validation, which can be time-consuming and resource-intensive. This restricts the exploration of the full natural immune repertoire, hindering the identification of novel therapeutic antibodies. </problem> <solution> TianTi Biotherapeutics addresses these challenges with its AbLink™, OptAb™, and Rapid VHH technology platforms, which enable efficient mining of the natural immune repertoire for high-affinity antibodies. These platforms enhance hit success rates in therapeutic discovery by generating diverse and functional antibody candidates without the need for mammalian cell validation. AbLink™ comprehensively screens the natural antibody repertoire, providing extensive epitope coverage and increased unique clones. OptAb™ leverages de novo library design for simultaneous humanization, optimization, and affinity maturation. Rapid VHH facilitates high-quality VHH antibody discovery through yeast engineering, capturing the natural diversity of Llama and Alpaca immune responses. </solution> <features> - **AbLink™:** Comprehensive screening of the natural antibody repertoire. - **AbLink™:** Extensive epitope coverage for diverse target binding. - **AbLink™:** Increased unique and rare clones, resulting in greater diversity. - **AbLink™:** High affinity and functionality of discovered antibodies. - **AbLink™:** Hit validation without the need for mammalian cells. - **OptAb™:** De novo library design leveraging public algorithms and in-house expertise. - **OptAb™:** Simultaneous humanization, optimization, and affinity maturation. - **Rapid VHH:** High-quality VHH antibody discovery. - **Rapid VHH:** Yeast engineering for high-level VHH expression. - **Rapid VHH:** Direct capture of natural Llama and Alpaca immune response diversity. - **Rapid VHH:** Customized selection strategies for rapid isolation of desired VHH hits. </features> <target_audience> The primary target audience includes pharmaceutical and biotechnology companies, as well as research institutions, seeking to discover and develop novel antibody therapeutics for various diseases. </target_audience> ```
What does do?
TianTi Biotherapeutics utilizes its AbLink™, OptAb™, and Rapid VHH technology platforms to efficiently mine the natural immune repertoire for high-affinity antibodies, enhancing hit success rates in therapeutic discovery. The company addresses the challenge of limited therapeutic options by generating diverse and functional antibody candidates without the need for mammalian cell validation.
- 0